Next Phase Newsletter

A venture fund focusing on the intersection between technology and life sciences is willing to invest globally, investing in seed-series A stages, but will consider series B opportunities as well. The firm will generally invest between $0.5-2M in seed stages, $3-5M in series A rounds, and may invest up to $15M over the lifetime of the investment.

The firm invests in solutions to complex problems in human and animal health. The firm partners with entrepreneurs and academic scientists across all stages of venture investing, and its investments span the full continuum of the healthcare ecosystem. Previously funded companies include a microbiome-based drug discovery platform, a company sequencing T-cell receptors to analyze immune function and a company developing a continuous monitoring system using a dermal patch.

The firm remains actively involved in companies after investing. The firm generally takes a board seat or board observer position in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A China-based VC focused exclusively on the biotech industry combines a deep understanding of drug development, industry networks, as well as regulatory expertise to help portfolio companies to achieve strategic goals efficiently. The partners of the fund have combined decades of drug industry experiences before establishing the firm in 2019. The fund invests in true innovations with a major impact on patients’ lives. The firm’s investment size can range from $1 M and up to $6 M, in which the typical size would be $3 M~$4 M. The firm is actively looking for new investment opportunities in North America and Europe. The firm can act as lead or co-investor.

Within biotech, the firm focuses on companies in pre-IND to phase II. The firm is opportunistic in all indications and willing to consider orphan indications.

The firm has no specific requirements for companies. The firm generally takes a board seat or an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC firm based in Paris invests primarily in seed/series A with significant follow-on capability.

The firm is now investing with two funds; the first fund is dedicated to investing in companies based in the Paris region across various sectors (digital, deeptech, life science), while the second fund is dedicated to investing in Digital Health companies in Western Europe. The firm generally invests between 0.3-1.5M EUR in the initial investment, and can invest up to 2-5M EUR overall in a company, and will invest in up to 10 companies a year.

The firm invests differently from their two current funds :

– The first fund is sector agnostic, and will invest in Life Science (therapeutics, diagnostics, devices and digital health companies) in the Paris region.
– The second fund covering Western Europe is focused primarily on digital health, due to the strategic interest of the fund investors in this area (several healthcare companies)

The firm can lead or co-invest, and do frequently lead. They will take a board seat in any case – the firm is an active investor providing hands-on support to its portfolio company (Strategy, HR, Financing, …).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2020 and based in USA is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with check sizes between 5 – 10 million USD. The firm prefers to lead the financing rounds but is open to co-investing. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital arm of a large corporation is interested in therapeutic, medical device, diagnostic, and digital health technologies. The firm usually participates in Seed to series C financing rounds with check sizes between $500K – 2M USD. The firm is open to both leading and co-investing and is aiming to make 15 investments in the next 12 months. The firm is open to global opportunities.

The firm is open to considering innovative technologies that address unmet medical needs in therapeutics, diagnostics, medical devices, and digital health. The firm’s greatest interest lies in the biotech and diagnostic sector in which the firm have the strongest expertise. For medical devices and diagnostics, the firm is open to any subsectors but is most interested in AI-based diagnostics and innovative genomics applications. The firm is open to any indication area including oncology, CNS diseases and rare diseases.

The firm seeks to work with companies with a sound business model and great execution, but will mainly focus on the merit of technologies and the team when working with very early-stage companies. The firm considers itself to be an active investor and will take a board seat depending on the cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based fund invests in both external venture capital funds, and also has a fund of $150 million from which to make direct investments in early stage companies. The firm focuses on investing in startups with some connection to universities near the fund but also makes some investments into outside startups.  Initial investments are typically made at an early stage, and most are from $250,000-1 million; the firm also makes follow-on investments. The firm invests primarily in the US and also considers opportunities in Canada.

The firm invests in a wide variety of technology sectors; in the life sciences, the fund is focused on diagnostics, medical devices, and innovative areas of digital health.  The firm is opportunistic and will consider life science innovations broadly; areas of high interest include cancer care, AI, machine learning, clinical decision support systems, and imaging.  The firm will consider investing at a very early stage of development.

The firm focuses on startups with a connection to local universities, and the organization has an additional innovation capital program for developing innovative technology in the US Midwest, including resources for incubating and accelerating new life science startups.  However, the firm also invests in startups that have no prior connection to such universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA focuses exclusively on early stage and seed investments in medical device companies. The firm provides seed, first, or second round of financing, typically in equity. The initial investment in a company ranges from $250K to $3M, with follow-on financing rounds. Accordingly, the firm invests between $2-6M over the life of an investment. The firm typically invests in companies that are based in the US, but may consider exceptional opportunities abroad. The firm is actively seeking new investment opportunities.

The firm is specifically looking for medical devices that address cardiovascular, orthopedic indications. The firm has no clinical requirements and will invest in design stage. The product must be based on strongly protected IP.

The firm prefers to invest in companies that are not looking to develop their own sales team, but rather developing a technology that can be sold at a healthy premium to a company which already has the requisite sales and marketing teams in place. The firm generally takes a board seat, but is not a requirement. In addition, the firm prefers to assume a role on the company’s scientific advisory board. The firm is looking for companies with a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.